Trial Profile
Single ascending dose study of the safety, tolerability, and pharmacokinetics of LXR-623 administered orally to healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2009
Price :
$35
*
At a glance
- Drugs LXR 623 (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Wyeth
- 22 Mar 2007 New trial record.